© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 18, 1344-1345,
September 18, 2002
© 2002 Oxford University Press
EDITORIAL |
Cancer Risks in BRCA1 Carriers: Time for the Next Generation of Studies
Affiliations of authors: S. B. Gruber, Departments of Internal Medicine and Epidemiology, Division of Molecular Medicine and Genetics, University of Michigan, Ann Arbor; G. M. Petersen, Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
Correspondence to: Stephen B. Gruber, M.D., Ph.D., M.P.H., Departments of Internal Medicine and Epidemiology, Division of Molecular Medicine and Genetics, University of Michigan, Ann Arbor, MI 48109-0638 (e-mail: sgruber@umich.edu).
| The first 150 words of the full text of this article appear below. |
Estimating the risk of cancer in individuals who carry a germline mutation in a cancer susceptibility gene or who are related to known mutation carriers has profound clinical implications. Each day, women and health care providers use information about the risks conferred by BRCA1 to help make intelligent choices regarding screening, chemoprevention, and risk-reducing surgery. Several studies have already demonstrated the measurable benefits of tamoxifen for women at high risk for breast and ovarian cancer (1) and a lowered risk in women who have undergone bilateral mastectomy (2) or salpingo-oophorectomy (3). Therefore, it makes sense to estimate risks as carefully and precisely as possible and to expand our knowledge of other cancer risks associated with BRCA1 in the hope that targeted strategies for risk reduction will also be relevant for these cancers.
Two articles in this issue of the Journal describe the lifetime
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Kadouri, A. Hubert, Y. Rotenberg, T. Hamburger, M. Sagi, C. Nechushtan, D. Abeliovich, and T. Peretz Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations J. Med. Genet., July 1, 2007; 44(7): 467 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C J van Asperen, R M Brohet, E J Meijers-Heijboer, N Hoogerbrugge, S Verhoef, H F A Vasen, M G E M Ausems, F H Menko, E B Gomez Garcia, J G M Klijn, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary J. Med. Genet., September 1, 2005; 42(9): 711 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Beger, M. Ramadani, S. Meyer, G. Leder, M. Kruger, K. Welte, F. Gansauge, and H. G. Beger Down-Regulation of BRCA1 in Chronic Pancreatitis and Sporadic Pancreatic Adenocarcinoma Clin. Cancer Res., June 1, 2004; 10(11): 3780 - 3787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Garber and S. Syngal One Less Thing to Worry About: The Shrinking Spectrum of Tumors in BRCA Founder Mutation Carriers J Natl Cancer Inst, January 7, 2004; 96(1): 2 - 3. [Full Text] [PDF]
|
|
|
|
|
|
T. Kirchhoff, J. M. Satagopan, N. D. Kauff, H. Huang, P. Kolachana, C. Palmer, H. Rapaport, K. Nafa, N. A. Ellis, and K. Offit Frequency of BRCA1 and BRCA2 Mutations in Unselected Ashkenazi Jewish Patients With Colorectal Cancer J Natl Cancer Inst, January 7, 2004; 96(1): 68 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Risch and S. A. Narod Re: Cancer Risks in BRCA1 Carriers: Time for the Next Generation of Studies J Natl Cancer Inst, May 21, 2003; 95(10): 758 - 758. [Full Text] [PDF]
|
|